The Zhitong Finance App learned that on Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) entered the US stock market. As of press release, the stock had risen more than 14% to $20.53. Latigo is committed to developing non-opioid pain relievers targeting the Nav1.8 sodium ion channel. Its core drug candidate, LTG-001, is an oral NaV1.8 inhibitor mainly used to treat moderate to severe acute pain, including postoperative pain. This medication is designed to provide analgesic effects comparable to opioids while avoiding the risk of addiction. Nav1.8 is mainly expressed in peripheral pain sensory neurons. Its inhibitors do not act on the central nervous system and are therefore not addictive.

The Zhitong Finance App learned that on Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) entered the US stock market. As of press release, the stock had risen more than 14% to $20.53. Latigo is committed to developing non-opioid pain relievers targeting the Nav1.8 sodium ion channel. Its core drug candidate, LTG-001, is an oral NaV1.8 inhibitor mainly used to treat moderate to severe acute pain, including postoperative pain. This medication is designed to provide analgesic effects comparable to opioids while avoiding the risk of addiction. Nav1.8 is mainly expressed in peripheral pain sensory neurons. Its inhibitors do not act on the central nervous system and are therefore not addictive.